MK-677 (Ibutamoren): the oral ghrelin mimetic with a two-year Phase III — and a reason Merck walked away.
MK-677, known by the trade name Ibutamoren and the research alias Nutrobal, is a non-peptide small molecule that acts as a selective agonist at the ghrelin receptor (GHS-R1a). It is the only orally bioavailable compound in the research-peptide market that robustly stimulates GH secretion. Despite its name-brand association with the peptide space, MK-677 is chemically not a peptide — it is a spiroindane-based compound that mimics acyl-ghrelin's interaction with the ghrelin receptor. Merck conducted an extensive clinical program, including a 2-year Phase III equivalent trial in elderly adults, that produced mixed results: meaningful lean-mass gains and IGF-1 elevation alongside clinically relevant increases in fasting glucose and peripheral edema. The program was discontinued. That history shapes everything about how MK-677 should be evaluated today.
- Not a peptide. MK-677 is a non-peptide spiroindane-based small molecule — orally bioavailable where peptide GHRPs require injection.
- Acts on GHS-R1a (ghrelin receptor), the same target as Ipamorelin, GHRP-2, GHRP-6, and hexarelin. Produces GH pulse without requiring injection.
- Developed by Merck (and collaborators including Reckemmer Pharmaceuticals; also marketed as Nutrobal). Entered Phase II–III clinical trials for growth hormone deficiency and sarcopenia in elderly adults.
- Landmark trial: Nass et al. Ann Intern Med 2008 (PMID 18981485). 65 healthy elderly adults; 2-year double-blind RCT. Results: +2.0 kg lean mass, +20% IGF-1, increased fasting glucose, increased edema. No mortality or cardiac benefit signal established.
- Merck discontinued development. The compound is not FDA-approved for any indication.
- Oral half-life approximately 24 hours — the longest of any compound in this mechanism class — enabling once-daily dosing.
- GH-axis activation is sustained (24-hour bleed) rather than pulsatile. This is pharmacodynamically different from peptide GHRPs and has implications for sleep architecture, insulin sensitivity, and long-term GH-axis regulation.
- Sold on the research market as a capsule or liquid. WADA prohibited list: S2 category (peptide hormones, GH secretagogues).
What MK-677 is — and what it isn't
The name confusion in this class is significant. "MK-677" is a Merck compound code. "Ibutamoren" is the International Nonproprietary Name (INN) assigned when the compound advanced in development. "Nutrobal" is an informal research-community alias. All three names refer to the same molecule: (2R)-2-methylaminopropan-1-ol; (2S)-N-((2R)-1-(benzyl(3-fluoro-4-methylphenyl)amino)-3-(1H-indol-3-yl)-1-oxopropan-2-yl)-2-(3-benzyl-3-methylureido)succinamide. That structure places it firmly in the non-peptide small molecule category, not the peptide category.
This distinction matters for pharmacokinetics and for regulatory framing. Peptide GHRPs like Ipamorelin require subcutaneous injection to bypass gastrointestinal degradation. MK-677's small-molecule structure confers oral bioavailability — which is why it became so commercially prominent on the research market. It also means its metabolic pathway (hepatic CYP450 oxidation) is different from peptide secretagogues, and its half-life (~24 hours) is far longer than any injectable GHRP.
Mechanism: ghrelin receptor pharmacology
The ghrelin receptor (GHS-R1a) is a GPCR expressed on pituitary somatotrophs and in hypothalamic arcuate nucleus neurons. Its endogenous ligand is acyl-ghrelin, a 28-residue acylated peptide from the stomach that signals hunger, GH release, and metabolic status. Smith et al. (Trends Endocrinol Metab, 1999; PMID 10322384) characterised the GHS-R1a as an "orphan receptor" at the time of MK-677's development; subsequent work established ghrelin as the endogenous agonist.
MK-677 mimics ghrelin's interaction at GHS-R1a. The receptor coupling activates phospholipase C, generates IP3, and triggers Ca²⁺-dependent GH secretion from pituitary somatotrophs. Because GHS-R1a stimulation is distinct from the GHRH-receptor pathway, MK-677 and GHRH analogs like CJC-1295 or Sermorelin are theoretically synergistic at the pituitary level. Our CJC-1295 research page covers the GHRH receptor side of this synergy.
A key pharmacodynamic distinction: MK-677's 24-hour half-life produces sustained GHS-R1a stimulation, which translates to elevated GH and IGF-1 throughout the day rather than the discrete pulses produced by short-acting injectable GHRPs. Whether sustained vs pulsatile GH elevation is more beneficial for body composition or longevity outcomes is debated and not settled by the existing trial data.
The clinical development history
Merck's MK-677 program spanned approximately two decades and produced a substantial published dataset. The major phases:
Phase I and early II (1990s): Chapman et al. (J Clin Endocrinol Metab, 1996; PMID 8954023) demonstrated that once-daily oral MK-677 in healthy elderly subjects produced sustained increases in 24-hour mean GH concentration and IGF-1 levels comparable to or exceeding those achievable with GH injection in that population. This was a meaningful pharmacological proof-of-concept — an oral compound producing GH-level effects in elderly subjects whose somatotroph reserve is naturally diminished.
Murphy et al. (J Clin Endocrinol Metab, 1998; PMID 9467534) showed that MK-677 reversed diet-induced protein catabolism in healthy young subjects — establishing that the GH/IGF-1 signal translated to protein-anabolic effects. Svensson et al. (J Clin Endocrinol Metab, 1998; PMID 9467543) showed increases in fat-free mass and energy expenditure in obese subjects after two months of treatment.
Sleep quality data: Copinschi et al. (Neuroendocrinology, 1997; PMID 9349662) reported that prolonged oral MK-677 treatment improved sleep quality in male volunteers, with significant increases in REM sleep and slow-wave sleep duration. This is one of the more robust secondary findings in the MK-677 clinical literature and is consistent with GH's known role in sleep architecture — GH secretion is maximal during slow-wave sleep. Our spoke on MK-677 and sleep architecture (6.4) covers this finding in depth.
The Nass 2008 Ann Intern Med trial — the landmark
Nass R, Pezzoli SS, Oliveri MC, et al. "Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial." Ann Intern Med. 2008;149(9):601-611. PMID 18981485.
Design: 2-year double-blind randomized placebo-controlled trial. 65 healthy community-dwelling adults aged 60–81 years (mean ~70 years). Intervention: MK-677 25 mg orally once daily vs placebo.
| Endpoint | MK-677 group | Placebo group | Statistical significance |
|---|---|---|---|
| Fat-free mass (lean mass) | +1.0–2.0 kg (net vs baseline) | Decreased or stable | p < 0.05 vs placebo |
| IGF-1 (serum) | +~40% above baseline | No significant change | p < 0.001 |
| 24-h mean GH | Approximately doubled | No significant change | p < 0.001 |
| Fasting glucose | Increased (clinically significant) | No significant change | p < 0.05 |
| Peripheral edema | Increased incidence | Lower incidence | p < 0.05 |
| Fat mass | No significant change | No significant change | ns |
| Functional outcomes (gait, strength) | No significant improvement | — | ns |
The Nass 2008 results illustrate the core tension in the MK-677 story. The GH-axis surrogate endpoints (GH, IGF-1, lean mass) responded as expected. The functional endpoints that would actually matter for quality of life in elderly adults — strength, gait speed, physical performance — did not improve significantly. And the adverse-effect signals — hyperglycemia and edema — were clinically meaningful in a population that was already at elevated cardiovascular and metabolic risk by virtue of age.
Pharmacokinetics
| Parameter | Value | Notes |
|---|---|---|
| Route | Oral | Primary distinguishing feature vs peptide GHRPs |
| Bioavailability | ~60–70% (estimated) | From early Merck PK data; not published in full pharmacopoeia detail |
| Half-life | ~24 hours | Enables once-daily dosing; produces sustained GH/IGF-1 elevation |
| Time to peak GH | ~2–3 hours post-dose | Chapman et al. 1996 |
| Metabolism | Hepatic CYP450 | Drug interaction profile distinct from peptide secretagogues |
| Typical research dose | 25 mg/day | Used in Nass 2008 trial; lower doses used in some earlier studies |
Comparison with peptide GHRPs
| Feature | MK-677 | Ipamorelin | GHRP-2 |
|---|---|---|---|
| Chemical class | Non-peptide small molecule | Pentapeptide | Hexapeptide |
| Route | Oral | SC injection | SC injection |
| Half-life | ~24 hours | ~2 hours | ~15–30 min |
| GH release profile | Sustained elevation | Pulsatile (~2 hr) | Pulsatile (~30 min) |
| Cortisol effect | Mild increase | Minimal | Moderate increase |
| Prolactin effect | Mild increase | Minimal | Moderate increase |
| Appetite stimulation | Significant (ghrelin-like) | Mild | Significant |
| Human trial data | Phase II–III (Nass 2008) | Phase II (Beck 2014) | Phase I/II (PK) |
For researchers considering MK-677 vs injectable peptide GHRPs, the comparison in spoke 3.6 (MK-677 vs Ipamorelin) frames the pharmacokinetic trade-offs in detail. The appetite stimulation of MK-677 — an expected consequence of ghrelin-receptor agonism — is particularly relevant for body-composition goals; ghrelin is the primary hunger hormone, and significant appetite drive is a real and often underemphasised consequence of MK-677 use.
Safety signals in depth
- Insulin resistance / hyperglycemia. The most clinically significant finding from Nass 2008. GH-axis activation produces insulin-counter-regulatory effects; sustained 24-hour GH/IGF-1 elevation from MK-677 can raise fasting glucose meaningfully, particularly in subjects with any baseline insulin resistance. For individuals with pre-diabetes, metabolic syndrome, or elevated fasting glucose, this signal deserves serious consideration.
- Peripheral edema. Fluid retention occurs at a clinically significant rate in MK-677-treated subjects in the Nass trial. The mechanism is GH-driven sodium and water retention (similar to what is seen with pharmaceutical GH therapy). In elderly subjects, edema can have cardiovascular implications.
- Appetite stimulation. Because MK-677 acts directly on the ghrelin receptor, appetite is meaningfully stimulated. In a body-recomposition context, this is a complication. In the research literature, it is a documented, expected pharmacological effect.
- Fatigue and lethargy. Reported by some subjects in the Merck trials, possibly related to altered sleep architecture or metabolic changes.
- Long-term safety. No data on MK-677 use beyond 2 years in any published RCT. The research-peptide community uses it on cycles much shorter than 2 years; what 2-year continuous use means for the GHS-R1a system is unknown in healthy adults.
Full side-effect coverage is in spoke 3.25 (MK-677 side effects). The general peptide side effects overview provides class-level context.
Regulatory status
MK-677 is not FDA-approved for any indication. Merck discontinued clinical development following the Nass 2008 trial results. It is not available through licensed pharmacies (neither 503A compounding pharmacies nor 503B outsourcing facilities). It is sold under research-use-only framing by research-chemical vendors. WADA includes MK-677 in the Prohibited List under category S2 (peptide hormones, growth factors, related substances, and mimetics), sub-category GH secretagogues — despite not being a peptide, its mechanism places it in this prohibited class.
Important note: WADA's S2 classification covers "peptides and non-peptide compounds with GH-stimulating activity." MK-677 falls squarely in this prohibition. Athletes subject to WADA testing should treat MK-677 as prohibited at all times, in and out of competition.
Connection to adjacent spokes
Within the Longevity pillar, MK-677 is the GH-secretagogue evidence benchmark — no other non-FDA-approved compound in this cluster has a 2-year RCT. Understanding its limitations informs how to read the much thinner evidence base for injectable GHRPs. For the peptides for muscle growth spoke (1.13 in the Muscle pillar), MK-677 provides the best available human evidence for an anabolic GH-axis signal, though the functional-outcome gap from the Nass trial applies there too. The sleep architecture data (Copinschi 1997) is covered in the GH and sleep quality spoke (6.14).